Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA

Yong Hee Yu, Eunjoong Kim, Dai Eui Park, Gayong Shim, Sangbin Lee, Young Bong Kim, Chan Wha Kim, Yu Kyoung Oh

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

In this study, we formulated cationic solid lipid nanoparticles (cSLN) for co-delivery of paclitaxel (PTX) and siRNA. 1,2-Dioleoyl-sn-glycero-3- ethylphosphocholine-based cSLN were prepared by emulsification solidification methods. PTX-loaded cSLN (PcSLN) were characterized by zeta potential and gel retardation of complexes with small interfering RNA (siRNA). The sizes of PcSLN did not significantly differ from those of empty cSLN without PTX (EcSLN). The use of cSLN increased the cellular uptake of fluorescent dsRNA in human epithelial carcinoma KB cells, with PcSLN complexed to fluorescence-labeled dsRNA promoting the greatest uptake. For co-delivery of therapeutic siRNA, human MCL1-specific siRNA (siMCL1) was complexed with PcSLN; luciferase-specific siRNA (siGL2) complexed to EcSLN or PcSLN was used as a control. MCL1 mRNA levels were significantly reduced in KB cells treated with siMCL1 complexed to PcSLN, but not in groups treated with siMCL alone or siGL2 complexed to PcSLN. siMCL1 complexed to PcSLN exerted the greatest in vitro anticancer effects in KB cells, followed by siMCL1 complexed to EcSLN, siGL2 complexed to PcSLN, PTX alone, and siMCL1 alone. In KB cell-xenografted mice, intratumoral injection of PcSLN complexed to siMCL1 significantly reduced the growth of tumors. Taken together, our results demonstrate the potential of cSLN for the development of co-delivery systems of various lipophilic anticancer drugs and therapeutic siRNAs.

Original languageEnglish
Pages (from-to)268-273
Number of pages6
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume80
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Paclitaxel
Nanoparticles
Small Interfering RNA
KB Cells
Lipids
Luciferases
Fluorescence
Gels
Carcinoma
Messenger RNA
Injections
Therapeutics
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Co-delivery
  • Combined cancer therapy
  • Paclitaxel
  • SiRNA
  • Solid lipid nanoparticles

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Cite this

Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. / Yu, Yong Hee; Kim, Eunjoong; Park, Dai Eui; Shim, Gayong; Lee, Sangbin; Kim, Young Bong; Kim, Chan Wha; Oh, Yu Kyoung.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 80, No. 2, 01.02.2012, p. 268-273.

Research output: Contribution to journalArticle

Yu, Yong Hee ; Kim, Eunjoong ; Park, Dai Eui ; Shim, Gayong ; Lee, Sangbin ; Kim, Young Bong ; Kim, Chan Wha ; Oh, Yu Kyoung. / Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. In: European Journal of Pharmaceutics and Biopharmaceutics. 2012 ; Vol. 80, No. 2. pp. 268-273.
@article{a82fb9a9ebe04172acc89b3c9fade30a,
title = "Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA",
abstract = "In this study, we formulated cationic solid lipid nanoparticles (cSLN) for co-delivery of paclitaxel (PTX) and siRNA. 1,2-Dioleoyl-sn-glycero-3- ethylphosphocholine-based cSLN were prepared by emulsification solidification methods. PTX-loaded cSLN (PcSLN) were characterized by zeta potential and gel retardation of complexes with small interfering RNA (siRNA). The sizes of PcSLN did not significantly differ from those of empty cSLN without PTX (EcSLN). The use of cSLN increased the cellular uptake of fluorescent dsRNA in human epithelial carcinoma KB cells, with PcSLN complexed to fluorescence-labeled dsRNA promoting the greatest uptake. For co-delivery of therapeutic siRNA, human MCL1-specific siRNA (siMCL1) was complexed with PcSLN; luciferase-specific siRNA (siGL2) complexed to EcSLN or PcSLN was used as a control. MCL1 mRNA levels were significantly reduced in KB cells treated with siMCL1 complexed to PcSLN, but not in groups treated with siMCL alone or siGL2 complexed to PcSLN. siMCL1 complexed to PcSLN exerted the greatest in vitro anticancer effects in KB cells, followed by siMCL1 complexed to EcSLN, siGL2 complexed to PcSLN, PTX alone, and siMCL1 alone. In KB cell-xenografted mice, intratumoral injection of PcSLN complexed to siMCL1 significantly reduced the growth of tumors. Taken together, our results demonstrate the potential of cSLN for the development of co-delivery systems of various lipophilic anticancer drugs and therapeutic siRNAs.",
keywords = "Co-delivery, Combined cancer therapy, Paclitaxel, SiRNA, Solid lipid nanoparticles",
author = "Yu, {Yong Hee} and Eunjoong Kim and Park, {Dai Eui} and Gayong Shim and Sangbin Lee and Kim, {Young Bong} and Kim, {Chan Wha} and Oh, {Yu Kyoung}",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.ejpb.2011.11.002",
language = "English",
volume = "80",
pages = "268--273",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA

AU - Yu, Yong Hee

AU - Kim, Eunjoong

AU - Park, Dai Eui

AU - Shim, Gayong

AU - Lee, Sangbin

AU - Kim, Young Bong

AU - Kim, Chan Wha

AU - Oh, Yu Kyoung

PY - 2012/2/1

Y1 - 2012/2/1

N2 - In this study, we formulated cationic solid lipid nanoparticles (cSLN) for co-delivery of paclitaxel (PTX) and siRNA. 1,2-Dioleoyl-sn-glycero-3- ethylphosphocholine-based cSLN were prepared by emulsification solidification methods. PTX-loaded cSLN (PcSLN) were characterized by zeta potential and gel retardation of complexes with small interfering RNA (siRNA). The sizes of PcSLN did not significantly differ from those of empty cSLN without PTX (EcSLN). The use of cSLN increased the cellular uptake of fluorescent dsRNA in human epithelial carcinoma KB cells, with PcSLN complexed to fluorescence-labeled dsRNA promoting the greatest uptake. For co-delivery of therapeutic siRNA, human MCL1-specific siRNA (siMCL1) was complexed with PcSLN; luciferase-specific siRNA (siGL2) complexed to EcSLN or PcSLN was used as a control. MCL1 mRNA levels were significantly reduced in KB cells treated with siMCL1 complexed to PcSLN, but not in groups treated with siMCL alone or siGL2 complexed to PcSLN. siMCL1 complexed to PcSLN exerted the greatest in vitro anticancer effects in KB cells, followed by siMCL1 complexed to EcSLN, siGL2 complexed to PcSLN, PTX alone, and siMCL1 alone. In KB cell-xenografted mice, intratumoral injection of PcSLN complexed to siMCL1 significantly reduced the growth of tumors. Taken together, our results demonstrate the potential of cSLN for the development of co-delivery systems of various lipophilic anticancer drugs and therapeutic siRNAs.

AB - In this study, we formulated cationic solid lipid nanoparticles (cSLN) for co-delivery of paclitaxel (PTX) and siRNA. 1,2-Dioleoyl-sn-glycero-3- ethylphosphocholine-based cSLN were prepared by emulsification solidification methods. PTX-loaded cSLN (PcSLN) were characterized by zeta potential and gel retardation of complexes with small interfering RNA (siRNA). The sizes of PcSLN did not significantly differ from those of empty cSLN without PTX (EcSLN). The use of cSLN increased the cellular uptake of fluorescent dsRNA in human epithelial carcinoma KB cells, with PcSLN complexed to fluorescence-labeled dsRNA promoting the greatest uptake. For co-delivery of therapeutic siRNA, human MCL1-specific siRNA (siMCL1) was complexed with PcSLN; luciferase-specific siRNA (siGL2) complexed to EcSLN or PcSLN was used as a control. MCL1 mRNA levels were significantly reduced in KB cells treated with siMCL1 complexed to PcSLN, but not in groups treated with siMCL alone or siGL2 complexed to PcSLN. siMCL1 complexed to PcSLN exerted the greatest in vitro anticancer effects in KB cells, followed by siMCL1 complexed to EcSLN, siGL2 complexed to PcSLN, PTX alone, and siMCL1 alone. In KB cell-xenografted mice, intratumoral injection of PcSLN complexed to siMCL1 significantly reduced the growth of tumors. Taken together, our results demonstrate the potential of cSLN for the development of co-delivery systems of various lipophilic anticancer drugs and therapeutic siRNAs.

KW - Co-delivery

KW - Combined cancer therapy

KW - Paclitaxel

KW - SiRNA

KW - Solid lipid nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84856619472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856619472&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2011.11.002

DO - 10.1016/j.ejpb.2011.11.002

M3 - Article

C2 - 22108492

AN - SCOPUS:84856619472

VL - 80

SP - 268

EP - 273

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 2

ER -